The short version of glucagon receptor fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-03. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Stability depends strongly on physical state. Dry powder is comparatively robust when held at -20 °C or below, desiccated and shielded from light; under those conditions degradation is slow and measured over years. Once dissolved, the peptide becomes far more vulnerable: backbone hydrolysis, oxidation of susceptible residues and aggregation all proceed faster in solution, and the rates climb with temperature and with pH far from neutral. Refrigerated storage at 2–8 °C extends usable life for short periods, and repeated freeze–thaw cycles are best avoided.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
化学修饰延长了分子在体内的停留时间，使较低频次的给药安排成为可能。脂肪酸侧链通过与白蛋白结合延缓清除，非天然氨基酸则降低酶解速率。这些修饰同时改变分子的溶解性与稳定性，需要在制剂设计和储存条件中一并考虑。修饰引入的免疫原性风险也属于开发过程中需要评估的项目。
该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
瑞他鲁肽同时激活GLP-1受体、GIP受体和胰高血糖素受体，这三者均属于B类G蛋白偶联受体。受体激活后主要经cAMP信号通路传递效应。GLP-1成分与食欲抑制和胃排空延缓相关，GIP成分影响脂肪组织与胰岛素分泌，胰高血糖素成分则促进肝糖输出和能量消耗。各受体贡献的相对比例在人体中尚未完全量化。
该分子是经过结构修饰的合成肽，通过脂肪酸侧链与白蛋白结合，从而延长循环时间。皮下给药后，药物逐步释放并分布至组织。降解主要依赖蛋白酶，肾脏清除占次要地位。人体半衰期以天为单位，但准确数值随检测方法和个体差异而变；组织分布与受体占有率仍是开放问题。
== External links == ImmPort - Gene summaries, ontologies, pathways, protein/protein interactions and more for genes involved in antigen processing and presentation antigen+presentation at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
== Clinical Significance == Single-nucleotide polymorphisms (SNPs) in the FGFR1OP2 gene were found to lead to edentulism in the mandible of a small Korean population (134 subjects aged 60–80 years). Also, when FGFR1OP2 is fused to FGFR1, 8p11 myeloproliferative syndrome can result.
==== Knight Commander of the Order of the Bath (KCB) ==== Military Division Lieutenant General Samuel Cowan, , (474845), late Royal Corps of Signals. Lieutenant General Hew William Royston Pike, . (472599), late The Parachute Regiment. Civil Division Richard Thomas James Wilson, , Permanent Under Secretary, Home Office.
== Personal life == Freeman came to Australia with his parents and his sister, Eva. Following the death of his father in 1958, he became a Director of K. H. Freeman Pty Ltd, which continues to operate today. He met Edith Siou in 1964 and they married in 1966. They have two children, Maeva and Philip.
Sources: en.wikipedia.org
=== Toluene hydrodealkylation === Toluene hydrodealkylation converts toluene to benzene. In this hydrogen-intensive process, toluene is mixed with hydrogen, then passed over a chromium, molybdenum, or platinum oxide catalyst at 500–650 °C and 20–60 atm pressure. Sometimes, higher temperatures are used instead of a catalyst (at the similar reaction condition). Under these conditions, toluene undergoes dealkylation to benzene and methane:
=== Protein binding === Meropenem has a low protein binding rate of approximately 2%, in contrast to ertapenem, which is about 90%. This pharmacokinetic difference may impact clinical outcomes, particularly in hypoalbuminemic patients. Observational studies have shown that, in this population, treatment with meropenem is associated with a significantly lower 30-day mortality rate compared to ertapenem, with an approximately fourfold reduction in risk.
=== Melanoma === Tumour-associated macrophages can be attracted by cytokines such as TGF-β and IL-10 produced by tumours in melanoma. These cytokines can also trigger the M2 polarisation of the infiltrated tumour-associated macrophages. Infiltrated macrophages that acquire the M2 phenotype are anti-inflammatory. They facilitate tumour growth and proliferation via immunosuppression, further cytokine production, and tumour angiogenesis. Tumour-associated macrophages also promote the invasion of cancer cells via the production of miRNA exosomes.
Storing food below or above the "danger zone" can effectively limit the production of toxins. For storing leftovers, the food must be put in shallow containers for quick cooling and must be refrigerated within two hours. When food is reheated, it must reach an internal temperature of 165 °F (74 °C) or until hot or steaming to kill bacteria.
Most specimens are of little value for research without accompanying information, such as the time and place the bird was found or collected. This and other important information, such as mass, sex, fat deposition, and degree of skull ossification, is written on a label along with a unique field and museum number. Modern computerized museum databases include all of this information for each specimen, as well as the types of methods used to prepare the bird. Modern collections seek to maximize the utility of each preserved individual, and this includes recording detailed information about it. Most modern specimens also include a tissue sample preserved for genetic study. Online access to collections' data is becoming increasingly available, and a cross-institutional database covering millions of computerized bird records is in development. Freeze drying of whole specimens, especially of small birds, has been adopted for use in teaching collections.
Sources: en.wikipedia.org
In 2018, the FDA approved the Dexcom G6 for use as a stand-alone CGM, and for integration with compatible insulin pumps, making it the first continuous glucose monitor capable of direct integration with insulin pumps. The G6 was also the first CGM to operate without the need for calibrations, removing the requirement for routine fingerstick blood tests. However, actual blood glucose levels can differ from the levels reported by the CGM. The difference is primarily due to the location of the Dexcom sensor in the subcutaneous space. The sugar level there lags behind the actual changes in the bloodstream. The device retained compatibility with Dexcom's existing mobile applications, including Dexcom Share, which allows users to share glucose data with others, and Dexcom Clarity, which provides long-term trend analysis and reports. As of 2025, the Dexcom G6 remains available. In addition, while previous Dexcom CGMs were compatible only with Tandem insulin pumps, the G6 expanded its integration to the Omnipod 5 system.
Under the Medical Service Act (의료법/醫療法), an oriental medical doctor, whose obligation is to administer oriental medical treatment and provide guidance for health based on oriental medicine, shall be treated in the same manner as a medical doctor or dentist. The Korea Institute of Oriental Medicine is the top research center of TCM in Korea.
Talks quickly broke down, and final efforts in October to achieve a settlement floundered; the Smith government remained unwilling to accept the five principles of independence, and the British government argued it would settle for nothing less. On 11 November 1965 the Cabinet of Rhodesia issued a unilateral declaration of independence (UDI). The UDI was immediately denounced as an "act of rebellion against the Crown" in the United Kingdom, and Wilson promised that the illegal action would be short-lived. However, given its self-governing status Rhodesia had no longer been within the United Kingdom's direct sphere of influence for some time, and the façade of continued British rule was rendered a constitutional fiction by UDI. In light of these circumstances, Wilson quickly realised his ability to assert direct leverage over the incumbent Rhodesian government was limited. On 12 October 1965, the United Nations General Assembly had noted the repeated threats of the Rhodesian authorities "to declare unilaterally the independence of Southern Rhodesia, in order to perpetuate minority rule", and called upon Wilson to use all means at his disposal (including military force) to prevent the Rhodesian Front from asserting independence. After UDI was proclaimed, UN officials branded the Rhodesian government as an "illegal racist minority regime" and called on member states to voluntarily sever economic ties with Rhodesia, recommending sanctions on petroleum products and military hardware.
==== MeSH D12.776.377.715.182 – beta-globulins ==== MeSH D12.776.377.715.182.100 – beta-2 microglobulin MeSH D12.776.377.715.182.160 – beta-thromboglobulin MeSH D12.776.377.715.182.200 – complement factor h MeSH D12.776.377.715.182.338 – hemopexin MeSH D12.776.377.715.182.580 – plasminogen MeSH D12.776.377.715.182.580.500 – angiostatins MeSH D12.776.377.715.182.624 – properdin MeSH D12.776.377.715.182.800 – sex hormone-binding globulin MeSH D12.776.377.715.182.839 – transferrin
== Veterinary use == Fentanyl is commonly used for analgesia and as a component of balanced sedation and general anesthesia in small animal patients. The short-acting nature, wide safety profile, lower rate of adverse effect compared to other opioids, and high potency make fentanyl one of the most effective and common analgesics in veterinary medicine; the ability to reduce the minimum alveolar concentration leads to fentanyl being commonly used in dogs that are elderly or have cardiovascular issues. Due to its short duration and quick onset, fentanyl is commonly used as a constant rate infusion or as a transdermal patch, with the latter being able to last 3 to 4 days. Fentanyl can provide sedation for dogs. Fentanyl is less common and has more adverse effects in livestock and equine compared to cats and dogs. In horses at analgesic doses tachycardia, restlessness, and excitement occur. Subcutaneous administration often causes pain, but a bicarbonate solution exists which does not cause pain when given subcutaneously. Fentanyl is highly lipophilic, about 1000 times more than morphine. In dogs it has low protein binding of 15.6% and a half-life of 2–6 hours. In cats the half-life is 2.5 hours. Fentanyl has poor oral bio-availability due to it being metabolized by the liver. Transdermal and transmucosal formulations are common for out-patients, although the latter's efficacy is not well supported by evidence.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
Purity is normally given as a percentage from reversed-phase HPLC, calculated as the main peak area relative to total peak area. Research-grade material is commonly specified at 95 per cent or higher, with tighter specifications available. The number is method-dependent and should be read alongside the chromatogram.